Floatz logo

Osimertinib

MET Alteration

Beijing Pearl Biotechnology Limited Liability CompanySmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the MET Alteration cohort.

Asset / SponsorPhaseRating
Vebreltinib
Apollomics Inc.
Phase 2CCC
Vert-002
Pierre Fabre Medicament
Phase 1/2CC
ans014004
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2CC
plb1004
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2CC

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →